Active DLBCL Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trial?

• Find Trials That Fit — Browse recruiting Diffuse Large B-Cell Lymphoma (DLBCL) trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Diffuse Large B-Cell Lymphoma (DLBCL) type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trial FAQ

What CAR-T therapies are available for DLBCL in clinical trials?

Three CAR-T products are FDA-approved for relapsed/refractory DLBCL: axicabtagene ciloleucel (axi-cel / Yescarta), tisagenlecleucel (tisa-cel / Kymriah), and lisocabtagene maraleucel (liso-cel / Breyanzi). Clinical trials are testing these agents in earlier lines of therapy (second-line for transplant-ineligible patients), next-generation 'armored' CAR-T constructs, allogeneic (off-the-shelf) CAR-T products, and dual-target CAR-T.

What are bispecific antibodies for DLBCL, and are there trials for them?

Bispecific antibodies simultaneously bind to a protein on cancer cells (CD20 or CD19) and a protein on T cells (CD3), bringing the two together so T cells can destroy the lymphoma. Epcoritamab (Epkinly) and glofitamab (Columvi) are FDA-approved for relapsed/refractory DLBCL. Trials are testing earlier use of bispecifics, combinations with other agents, and novel bispecific constructs.

Do I need to be transplant-eligible to join a DLBCL clinical trial?

No. Historically, autologous stem cell transplant was the standard of care for relapsed DLBCL, and eligibility was a key factor. However, CAR-T and bispecific antibody trials now specifically enroll transplant-ineligible patients (due to age, fitness, or patient preference). There are separate trials for transplant-eligible and transplant-ineligible patients.

Does cell-of-origin (GCB vs. ABC/non-GCB) matter for DLBCL trial eligibility?

Yes, for some trials. Gene expression profiling classifies DLBCL into germinal center B-cell (GCB) and activated B-cell (ABC/non-GCB) subtypes, which have different biology and prognosis. Some trials target ABC-DLBCL (which is associated with NF-κB pathway activation and responds to BTK inhibitors) while others enroll all DLBCL subtypes. Your pathology report should include this information.

How long does it take to get on a DLBCL clinical trial?

The enrollment timeline varies by trial and site but typically takes 2–4 weeks from first contact to starting treatment, which may include re-biopsy, screening labs, and insurance approval. CAR-T manufacturing takes 3–6 weeks after cell collection, so early referral is important if you may be a candidate. Trialify can help you identify options quickly so you don't lose the treatment window.

Explore Other Cancer Trial Guides

• Lymphoma — Lymphoma trials are studying CAR-T cell therapies, bispecific antibodies, and targeted agents for both Hodgkin and non-Hodgkin subtypes — including diffuse large B-cell, follicular, and mantle cell lymphoma.
• Leukemia — Leukemia trials are testing targeted inhibitors, CAR-T therapies, and novel transplant strategies for AML, ALL, CLL, and CML. New treatment options are emerging rapidly across all leukemia types.
• Multiple Myeloma — Multiple myeloma trials are advancing CAR-T therapies, bispecific antibodies, BCMA-targeted agents, and novel triplet combinations — offering new paths for newly diagnosed and relapsed/refractory patients.
• Breast Cancer — Breast cancer trials are testing innovative therapies for all subtypes — HER2+, triple-negative (TNBC), and hormone receptor-positive. New options are opening every month at cancer centers across the country.